Biogen Inc. vs Abbvie Inc.
BIIB vs ABBV — side-by-side comparison from reported financials. BIIB leads 3, ABBV leads 7 of 10 comparable metrics.
Biogen Inc.
BIIB · Healthcare
$225.71+3.33%Strained
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
| Metric | BIIB | ABBV |
|---|---|---|
| Price | $225.71 | $276.43 |
| Market cap | $33.4B | $488B |
| Revenue (TTM) | $10.0B | $64.4B |
| Revenue growth | -0.9% | +1.8% |
| Net margin | 8.3% | 9.8% |
| Free cash flow | $2.70B | $18.2B |
| Net cash (debt) | $807M | ($56.2B) |
| 1-year price return | +50.9% | +19.8% |
| P/E | 40.0 | 77.4 |
| P/E vs own history (cheap-side %) | 1% | 23% |
| Dividend yield | — | 2.45% |
| Return on equity | 5% | 96% |
| Altman Z-score | — | 2.33 |
| CV checks passed | 8 of 10 | 9 of 10 |
| Employees | 7,500 | 57,000 |
Full résumé-style profiles: BIIB CV · ABBV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.